Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients-Reference-Cited by-同舟云学术

Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients

Published:2022-02-01 Issue:2 Volume:322 Page:F138-F149
ISSN:1931-857X
Container-title:American Journal of Physiology-Renal Physiology
language:en
Short-container-title:American Journal of Physiology-Renal Physiology

Author:

Thangaraj Sai Sindhu¹^ORCID,Thiesson Helle Charlotte²³,Svenningsen Per¹^ORCID,Stubbe Jane¹,Palarasah Yaseelan⁴,Bistrup Claus²³^ORCID,Jensen Boye L.¹^ORCID,Mortensen Line Aas²^ORCID

Affiliation:

1. Department of Cardiovascular and Renal Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark

2. Department of Nephrology, Odense University Hospital, Odense, Denmark

3. Faculty of Health Science, Department of Clinical Research, University of Southern Denmark, Odense, Denmark

4. Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark

Abstract

The mineralocorticoid receptor antagonist spironolactone had no direct anti-inflammatory effects on prohypertensive interleukin-17A or distal nephron epithelial injury markers in kidney transplant recipients.

Funder

Region of Southern Denmark

Novo Nordisk Fonden

A.P. Møller Fund

Odense University Hospital

Helen and Ejnar Bjørnows Fund

King Christian X Fund

Danish Medical Association

The Medicine Fund of the Danish Region

University of Southern Denmark

Publisher

American Physiological Society